STOCK TITAN

Fractyl Health (GUTS) Stock Price, News & Analysis

GUTS NASDAQ
Published by Stock Titan Data refreshed

Why is GUTS Stock Up Today?

17.31% today
22 alerts
2.6x vol
15m delay

Fractyl Health’s November 12 update highlighted Revita’s six-month trial endpoint, but the announcement came after market close on November 12. A subsequent 8-K disclosed plans to reduce the workforce by approximately 45% and lower quarterly operating cash spending.

AI-generated explanation by Rhea-AI, written on at . How Rhea-AI works. Not financial advice.

Price Move History

Daily moves over 5%
81 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
-68% close of January 29, 2026
1-year change
-93.3% closing prices, November 13, 2025 to November 13, 2026
1-month change
-77.6% closing prices, October 13, 2026 to November 13, 2026

Company Description

Fractyl Health, Inc. (Nasdaq: GUTS) is a biotechnology company in the healthcare sector that describes itself as a metabolic therapeutics company. Fractyl Health focuses on pioneering new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). Across its public disclosures, the company states that its goal is to move metabolic disease care away from chronic symptomatic management and toward durable, disease‑modifying therapies that address organ‑level root causes of disease.

Metabolic disease focus and therapeutic philosophy

According to multiple company communications, Fractyl Health is focused on obesity and T2D, which it characterizes as rapidly growing drivers of morbidity and mortality. The company emphasizes a strategy aimed at targeting organ‑level mechanisms that contribute to metabolic dysfunction. Rather than concentrating only on ongoing pharmacologic symptom control, Fractyl Health describes its objective as enabling durable remission and long‑term metabolic control through interventions designed to modify underlying disease biology.

Revita®: duodenal mucosal resurfacing for post‑GLP‑1 weight maintenance

Fractyl Health’s lead product candidate is Revita®, which the company describes as an outpatient endoscopic therapy based on its insights into the role of the gut in obesity. Revita is designed to remodel the duodenal lining via hydrothermal ablation, also referred to as duodenal mucosal resurfacing. Company materials state that this procedure is intended to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high‑fat and high‑sugar diets, which Fractyl Health identifies as a root cause of metabolic disease.

In the United States, Fractyl Health reports that Revita is for investigational use only under U.S. law. The company further notes that Revita has received U.S. Food and Drug Administration (FDA) Breakthrough Device designation in weight maintenance for people with obesity who discontinue GLP‑1‑based drugs. Fractyl Health is studying Revita in the REMAIN weight maintenance program, including the REMAIN‑1 Midpoint and Pivotal Cohorts and the open‑label REVEAL‑1 Cohort, to evaluate its potential to maintain weight loss after GLP‑1 drug discontinuation and to support a potential Premarket Approval (PMA) filing.

Clinical programs and study designs

Public updates from Fractyl Health describe several clinical efforts around Revita:

  • REVEAL‑1 Cohort: An open‑label study in individuals with obesity who have lost at least 15% of their total body weight on a GLP‑1 medication and who either need or choose to discontinue GLP‑1 therapy. After stopping the GLP‑1 drug, participants receive Revita, with the cohort designed to provide early, real‑world insights into post‑GLP‑1 weight maintenance.
  • REMAIN‑1 Midpoint Cohort: A randomized, double‑blind, sham‑controlled pilot study in adults with obesity who are initiated on tirzepatide at enrollment, treated to achieve at least 15% total body weight loss, then discontinue tirzepatide and are randomized 2:1 to Revita or a sham procedure. The key efficacy endpoint is total body weight change at three months, and the cohort is intended to provide early randomized evidence for Revita’s potential in post‑GLP‑1 weight maintenance.
  • REMAIN‑1 Pivotal Cohort: A larger randomized, double‑blind, sham‑controlled pivotal study designed to evaluate Revita’s safety and efficacy in maintaining weight loss after GLP‑1 discontinuation. The first co‑primary endpoint is defined as the percent of total body weight regain from the time of tirzepatide discontinuation in Revita versus sham patients through six‑month follow‑up.
  • Germany Real‑World Registry: A prospective, post‑market clinical follow‑up study of Revita in patients with inadequately controlled T2D, with entry criteria that include baseline hemoglobin A1c and body mass index thresholds and use of at least one glucose‑lowering agent.

Fractyl Health has reported positive randomized three‑month data from the REMAIN‑1 Midpoint Cohort and open‑label data from REVEAL‑1, which it describes as demonstrating the potential for Revita to help maintain weight loss and metabolic control after GLP‑1 discontinuation. The company also notes that Revita has shown favorable tolerability in these studies, with no procedure‑related serious adverse events reported in the summarized data.

Rejuva® gene therapy platform

In addition to Revita, Fractyl Health is developing its Rejuva® platform, which it describes as a next‑generation adeno‑associated virus (AAV)‑based, locally delivered gene therapy approach for obesity and T2D. Company disclosures state that Rejuva is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use.

Fractyl Health reports that Rejuva is designed to enable long‑term remission of T2D and obesity by durably reprogramming pancreatic islet cells to endogenously produce metabolic hormones. The platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The company highlights two named candidates:

  • RJVA‑001: A lead Rejuva candidate being advanced for patients with inadequately controlled T2D. Fractyl Health has submitted the first Clinical Trial Application (CTA) module for RJVA‑001 in T2D to regulators and has stated that, subject to CTA authorization, it expects to proceed to first‑in‑human evaluation.
  • RJVA‑002: A dual GIP/GLP‑1 gene therapy candidate for obesity that encodes both hormones under an engineered human insulin promoter to enable beta cell‑specific, nutrient‑responsive expression. In preclinical diet‑induced obesity models with a humanized GIP receptor, Fractyl Health reports that a single administration of RJVA‑002 produced substantial weight loss over several weeks, with no adverse effects observed in the summarized animal data.

Through these programs, Fractyl Health presents a multi‑modality strategy that combines device‑based intervention in the gut with gene therapy approaches directed at the pancreas, all aimed at addressing the biological drivers of obesity and T2D.

Intellectual property and corporate footprint

Across multiple press releases and filings, Fractyl Health states that it has a robust and growing intellectual property portfolio. The company reports dozens of granted U.S. patents and numerous pending U.S. and foreign patent applications covering its technologies, including Revita and the Rejuva platform. Fractyl Health is based in Burlington, Massachusetts, and its common stock trades on The Nasdaq Global Market under the symbol GUTS.

Capital markets activity and cash runway

Fractyl Health’s SEC filings and news releases describe several equity financings and warrant structures designed to support its clinical and regulatory milestones. These include underwritten offerings of common stock with associated Tranche A and Tranche B warrants, as well as subsequent calls of certain warrants after specified clinical and trading performance conditions were met. The company has disclosed that it expects its cash and cash equivalents, including proceeds from these financings and warrant exercises, to fund operations into early 2027, supporting planned clinical and regulatory activities for Revita and Rejuva.

Regulatory filings and public company status

Fractyl Health files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including Forms 8‑K related to clinical data releases, financing transactions, warrant calls, board changes, and special stockholder meetings. The company’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market. Recent filings include descriptions of its underwriting agreements, warrant terms, proxy solicitations for warrant‑related stockholder approvals, and Regulation FD disclosures regarding clinical and preclinical data.

Position within biotechnology and metabolic therapeutics

Within the biotechnology industry, Fractyl Health characterizes itself as focused on pattern‑breaking approaches that treat root causes of obesity and T2D. Its public communications emphasize the concept of post‑GLP‑1 weight maintenance as an emerging therapeutic category, with Revita positioned as a potential first therapy in this area, and its Rejuva platform aimed at long‑term metabolic control through gene therapy. Investors and observers use the GUTS stock overview to understand how these investigational programs, intellectual property, and financing activities align with the company’s stated objective of redefining treatment paradigms in metabolic disease.

Stock Performance

$1.06
+17.31%
+0.16
Last updated: November 16, 2026 at 12:11
-93.3%
Performance 1 year
$14.1M

Fractyl Health (GUTS) closed at $0.9036 on November 13, 2026. Over the past 12 months, the price has lost 93.3%.

See what a $1,000 investment in GUTS would be worth today

Average down calculator for GUTS

GUTS Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Fractyl Health has 10 recent news articles, with the latest published 4 days ago. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, earnings date, clinical trial. View all GUTS news →

SEC Filings

Fractyl Health has filed 10 recent SEC filings, including 6 Form 8-K, 1 Form 3, 1 Form SCHEDULE 13G/A, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all GUTS SEC filings →

Insider Radar

Net Buyers
90-Day Summary
64,516
Shares Bought
0
Shares Sold
1
Transactions
Most Recent Transaction
BRADLEY WILLIAM (Director) bought 64,516 shares @ $0.6185 on September 14, 2026

Insider buying activity at Fractyl Health over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Fractyl Health reported operating income of -$96.8M in FY2025, and net income was -$141.0M. Diluted earnings per share stood at -$22.32. The company generated -$90.3M in operating cash flow. The current ratio was 4.78, measuring current assets divided by current liabilities.

$0
Revenue (FY2025)
-$141.0M
Net Income (FY2025)
-$90.3M
Operating Cash Flow
$0
Gross Profit (FY2025)

Upcoming Events

DEC
2026
December 2026 Regulatory

Potential FDA marketing application

Potential submission of FDA marketing application for Revita per company guidance.
DEC
2026
December 2026 Regulatory

Potential De Novo submission

Planned potential FDA De Novo submission in late Q4 2026; favorable pre-submission feedback noted.
DEC
2026
December 2026 Regulatory

Potential De Novo application

Potential De Novo marketing application expected late Q4 2026; timing contingent on REMAIN-1 topline data and FDA discussions.
DEC
2026
December 2026 Regulatory

FDA De Novo submission

Potential FDA De Novo submission in late Q4 2026; Fractyl may file based on Pivotal results; timing is subject to review.
DEC
2026
December 2026 Regulatory

De Novo application

Fractyl plans to file an FDA De Novo marketing application in late Q4 2026; timing indicated as Dec 2026 window.
DEC
2026
December 2026 Regulatory

FDA De Novo filing

Company plans for a potential FDA De Novo marketing application in late Q4 2026 (target window Dec 2026).
Q1
2027
Q1 2027 Clinical

One-year data release

Fractyl expects one-year REMAIN-1 data in Q1 2027, including the second co-primary endpoint and extended safety/effectiveness results.
Q1
2027
Q1 2027 Clinical

12-month pivotal data

Fractyl expects 12-month pivotal REMAIN-1 data, including second co-primary endpoint, in Q1 2027; key trial readout.
Q1
2027
Q1 2027 Clinical

12-month topline results

12-month topline results for REMAIN-1 pivotal cohort expected Q1 2027, will include second co-primary endpoint versus sham.
JAN
01
January 1, 2027 Regulatory

CPT code 1122T effective

New Category III CPT code 1122T takes effect 2027-01-01, supporting potential reimbursement pathways for Revita procedure.
Q2
2027
Q2 2027 Financial

Funding runway milestone

Company expects cash to fund operations into Q2 2027, subject to minimum liquidity covenant.
Q2
2027
Q2 2027 Financial

Cash runway end

Company expects existing cash to fund operations into Q2 2027; runway effectively through the end of Q2 2027.
YEAR
2027
2027 Regulatory

Potential authorization

Company identifies late 2027 as potential timing for regulatory authorization for Revita; authorization window range.
Q4
2027
Q4 2027 Regulatory

Potential FDA authorization

Company targets potential FDA authorization in late 2027 pending agency review of complete REMAIN-1 safety and efficacy dataset.
YEAR
2028
2028 Product

Potential U.S. launch

Fractyl targets a potential U.S. commercial launch of Revita in early 2028, contingent on FDA authorization and final commercialization plans.
YEAR
2028
2028 Product

U.S. launch window

Fractyl targets early 2028 for a potential U.S. launch of Revita pending authorization; launch window Jan–Apr 2028.

Fractyl Health has 16 upcoming scheduled events. The next event, "Potential FDA marketing application", is expected in December 2026. 2 of them are financing or capital events, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the GUTS stock price.

Short Interest History

Last 12 Months

Short interest in Fractyl Health (GUTS) currently stands at 585.1 thousand shares, up 120.4% from the previous reporting period, representing 4.6% of the float.

Days to Cover History

Last 12 Months

Days to cover for Fractyl Health (GUTS) currently stands at 1.0 days, down 17.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 73.8%. Across the settlements charted above, it has ranged from 1.0 to 4.9 days.

GUTS Company Profile & Sector Positioning

Fractyl Health (GUTS) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing GUTS often look at related companies in the same sector, including BioCardia, Inc. (BCDA), Chemomab Therapeutics Ltd. (CMMB), Cellectar Biosciences INC NEW (CLRB), Anebulo Pharmac Inc (ANEB), and Palatin Technologies, Inc. (PTN). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate GUTS's relative position within its industry.

Frequently Asked Questions

The current stock price of Fractyl Health (GUTS) is $1.06 as of November 16, 2026.

The market cap of Fractyl Health (GUTS) is approximately $14.1M. Learn more about what market capitalization means .

The FY2025 revenue of Fractyl Health (GUTS) is $0, from its most recent completed fiscal year.

The FY2025 net income of Fractyl Health (GUTS) is -$141.0M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Fractyl Health (GUTS) is -$22.32 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Fractyl Health (GUTS) is -$90.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Fractyl Health (GUTS), current assets divided by current liabilities, was 4.78 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Fractyl Health (GUTS) is $0 for FY2025, its most recent completed fiscal year.

The operating income of Fractyl Health (GUTS) is -$96.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

Fractyl Health, Inc. describes itself as a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The company’s stated goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease‑modifying therapies that target organ‑level root causes of disease.

Revita is Fractyl Health’s lead product candidate, described as an outpatient endoscopic therapy based on the company’s insights into the role of the gut in obesity. It is designed to remodel the duodenal lining via hydrothermal ablation, or duodenal mucosal resurfacing, to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high‑fat and high‑sugar diets, which the company identifies as a root cause of metabolic disease.

Fractyl Health states that in the United States, Revita is for investigational use only under U.S. law. The company also reports that Revita has received U.S. FDA Breakthrough Device designation in weight maintenance for people with obesity who discontinue GLP‑1‑based drugs, and that it is being evaluated in the REMAIN‑1 pivotal program and related cohorts.

The Rejuva platform is Fractyl Health’s gene therapy program, which it describes as a next‑generation adeno‑associated virus (AAV)‑based, locally delivered gene therapy approach for obesity and type 2 diabetes. According to company disclosures, Rejuva is in preclinical development and is designed to enable long‑term remission by durably reprogramming pancreatic islet cells to endogenously produce metabolic hormones.

Fractyl Health identifies RJVA‑001 as its first Rejuva candidate being advanced for patients with inadequately controlled type 2 diabetes, subject to regulatory authorization of its Clinical Trial Application. RJVA‑002 is described as a dual GIP/GLP‑1 gene therapy candidate for obesity that has shown substantial weight loss in preclinical diet‑induced obesity models after a single administration.

Fractyl Health reports several studies evaluating Revita, including the REVEAL‑1 open‑label cohort in individuals with obesity who have lost at least 15% of body weight on a GLP‑1 medication and then discontinue it, the REMAIN‑1 Midpoint Cohort which is a randomized, double‑blind, sham‑controlled pilot study in adults with obesity treated with tirzepatide before discontinuation and randomization, and the REMAIN‑1 Pivotal Cohort, a larger randomized, double‑blind, sham‑controlled study designed to assess Revita’s safety and efficacy in maintaining weight loss after GLP‑1 discontinuation.

Fractyl Health highlights post‑GLP‑1 weight maintenance as a major unmet need in obesity care, noting that many patients are expected to start and then stop GLP‑1‑based drugs. The company positions Revita as a potential therapy to address weight regain after GLP‑1 discontinuation and presents its Rejuva platform as a way to pursue long‑term control of obesity and type 2 diabetes without chronic drug therapy.

Fractyl Health states that it is based in Burlington, Massachusetts. Its common stock is listed on The Nasdaq Global Market under the trading symbol GUTS.

In its public communications, Fractyl Health reports that it has a robust and growing intellectual property portfolio, including dozens of granted U.S. patents and numerous pending U.S. patent applications, along with foreign issued patents and pending applications, covering its metabolic therapeutics technologies such as Revita and the Rejuva platform.

Fractyl Health’s SEC filings and press releases describe underwritten offerings of common stock with associated Tranche A and Tranche B warrants, as well as the subsequent call of certain warrants once specified clinical and trading conditions were met. The company has stated that net proceeds from these financings, together with existing cash and cash equivalents, are expected to fund operations into early 2027 and support planned clinical and regulatory milestones for Revita and Rejuva.